Edge Advisors’s Boston Scientific BSX Stock Holding History

Edge Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$23K	Hold	720	–	–	﹤0.01%	616
2018 Q1	$18K	Hold	720	–	–	﹤0.01%	654
2017 Q4	$17K	Hold	720	–	–	﹤0.01%	689
2017 Q3	$20K	Hold	720	–	–	﹤0.01%	656
2017 Q2	$19K	Hold	720	–	–	﹤0.01%	665
2017 Q1	$17K	Sell	720 -354	-33%	-$8.61K	﹤0.01%	692
2016 Q4	$22K	Buy	+1,074	New	+$23.4K	﹤0.01%	612

Other funds holding BSX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Edge Advisors's BSX Position: Q2 2018 in Review

Edge Advisors held its Boston Scientific (BSX) position steady in Q2 2018 at 720 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #616.

Edge Advisors first reported a position in BSX in Q4 2016 and has held it in 7 quarters since. 671 funds tracked by Wall St. Rank hold BSX as of Q2 2018.

Edge Advisors held 720 shares of Boston Scientific worth $23K as of Q2 2018.
Edge Advisors left its Boston Scientific share count unchanged in Q2 2018.
Boston Scientific made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #616 holding.
Edge Advisors first reported a position in Boston Scientific in Q4 2016 and has held it in 7 quarters since.
671 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.